Company Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States.
It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy.
It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor.
The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.
I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | China |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 220 |
| CEO | Skelton Joseph |
Contact Details
Address: Suite 400, 2440 Research Blvd Rockville, Maryland 20850 United States | |
| Phone | (301) 670 2800 |
| Website | i-mabbiopharma.com |
Stock Details
| Ticker Symbol | IMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $14.00 |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raj Kannan | Chief Executive Officer and Director |
| Dr. Jerry Wang | Co-Founder and Chief Scientific Officer |
| Skelton Joseph | Chief Financial Officer |
| Tianyi Zhang | Vice President of Investor Relations |
| Dr. Fernando J. Salle´s Ph.D. | Senior Vice President and Head of U.S. and EU Business Development |
| Claire Xu | Head of US site |
| Dr. John Hayslip M.D. | Chief Medical Officer |
| Min Yin | Senior Vice President of Operations |
| Tyler Ehler | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 144 | Filing |
| Jul 15, 2024 | 6-K | Report of foreign issuer |
| Jun 6, 2024 | 6-K | Report of foreign issuer |
| Jun 5, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 23, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 15, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 6-K | Report of foreign issuer |